Ionis Pharmaceuticals, Inc. Common Stock
Market cap $7.5B
$46.47
IONS
$46.47
+3.64% today
Buy with €1M virtual cash · No real money
Ionis Pharmaceuticals, Inc. Common Stock (IONS) is a publicly traded company listed on the XNAS. As of September 17, 2026, Invest's signal rates IONS a Sell, with the stock down 24% over the past year. You can practice trading IONS risk-free with €1,000,000 in virtual cash.
Key stats
As of September 17, 2026
Market Cap
$7.5B
Volume
2.2M
52-wk High
$86.74
52-wk Low
$44.66
Day High
$47.42
Day Low
$45.75
Revenue (TTM)
$874.1M
EPS (TTM)
$-3.46
Performance
1M
-22.1%
6M
-35.2%
1Y
-24.2%
Invest signal · IONS
SellAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
IONS overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev +8.9%Revenue
$268MEPS (diluted)
$-0.69 per shareLatest IONS news
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Zacks Investment Research · 6h ago
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
GlobeNewswire Inc. · 2d ago
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
Zacks Investment Research · Sep 9
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
Zacks Investment Research · Sep 7
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
GlobeNewswire Inc. · Sep 4
About Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023.
Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Employees
1,402
30-Day Win Rate · IONS
9 days
15 days
Last 24 sessions
How to practice trading IONS
- 1
Use the IONS buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top IONS traders on Invest
Full leaderboardFrequently asked questions
Is IONS a good stock to buy right now?
As of September 17, 2026, Invest's signal rates IONS a Sell, based on its price trend, valuation, and fundamentals, with the stock down 24% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading IONS risk-free first.
What is Ionis Pharmaceuticals, Inc. Common Stock's (IONS) market cap?
Ionis Pharmaceuticals, Inc. Common Stock has a market capitalization of approximately $7.5B, on trailing-twelve-month revenue of about $874.1M.
How has IONS stock performed?
IONS is down 24% over the past year and down 35% over six months. Its 52-week range runs roughly from $44.66 to $86.74. Past performance doesn't predict future results.
How can I practice trading IONS for free?
On Invest you get €1,000,000 in virtual cash and can buy IONS at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.